ReCor Medical adds 4 directors to its medical advisory board, tasking the 9-member committee with conducting clinical studies of its next-generation renal denervation system.

 ReCor Medical adds 4 to expand its medical advisory board
ReCor Medical, which is backed by one of the largest life science investors in Europe in developing novel therapeutic ultrasound catheter technology, added 4 directors to its medical advisory board, which is now comprised of 9 members.

The board will conduct post-market clinical studies of ReCor's next-generation Paradise percutaneous renal denervation system, the only renal denervation device based on ultrasound.